Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 1, 2011, Pages 32-40

  Davern, S ^a   Murphy, C L ^a   O'Neill, H ^b   Wall, J S ^a   Weiss, D T ^a   Solomon, A ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Adhesion; AL amyloidosis; Human cells; Light chain; Lysine modification; Stability

Indexed keywords

BIOTIN; LYSINE;

AMYLOIDOSIS; ARTICLE; BIOTINYLATION; CASE REPORT; CHEMICAL MODIFICATION; CIRCULAR DICHROISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; AMYLOIDOSIS; BENCE JONES PROTEIN; BIOTINYLATION; CELL LINE; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; CIRCULAR DICHROISM; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LYSINE; MALE; MASS SPECTROMETRY; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; SEQUENCE HOMOLOGY, AMINO ACID; THERMODYNAMICS;

EID: 78650295571     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.07.022     Document Type: Article

References (41)

1. Obici L., Perfetti V., Palladini G., Moratti R., Merlini G. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta 2005, 1753:11-22.
2. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995, 32:45-59.
3. Enqvist S., Sletten K., Stevens F.J., Hellman U., Westermark P. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE 2007, 2:e981.
4. Comenzo R.L., Zhang Y., Martinez C., Osman K., Herrera G.A. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001, 98:714-720.
5. Omtvedt L.A., Bailey D., Renouf D.V., Davies M.J., Paramonov N.A., Haavik S., Husby G., Sletten K., Hounsell E.F. Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 2000, 7:227-244.
6. Foss G.S., Nilsen R., Cornwell G.C., Husby G., Sletten K. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues. Scand. J. Immunol. 1998, 47:348-354.
7. Connors L.H., Jiang Y., Budnik M., Theberge R., Prokaeva T., Bodi K.L., Seldin D.C., Costello C.E., Skinner M. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kapp a1 immunoglobulin light chains. Biochemistry 2007, 46:14259-14271.
8. Lim A., Wally J., Walsh M.T., Skinner M., Costello C.E. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kapp a1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal. Biochem. 2001, 295:45-56.
9. Kamalvand G., Ali-Khan Z. Immunolocalization of lipid peroxidation/advanced glycation end products in amyloid A amyloidosis. Free Radic. Biol. Med. 2004, 36:657-664.
10. Qin Z., Hu D., Han S., Reaney S.H., Di Monte D.A., Fink A.L. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 2007, 282:5862-5870.
11. Munch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Muller R., Neumann A., Schinzel R., Cunningham A.M. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta 1997, 1360:17-29.
12. Qahwash I.M., Boire A., Lanning J., Krausz T., Pytel P., Meredith S.C. Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. J. Biol. Chem. 2007, 282:36987-36997.
13. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., Leisner C., Lutkepohl T., Shtrasburg S., Rocken C., Pras M., Linke R.P., Diekmann S., Fandrich M. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl Acad. Sci. USA 2005, 102:6297-6302.
14. Sasaki A., Iijima M., Yokoo H., Shoji M., Nakazato Y. Human choroid plexus is a uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study. Brain Res. 1997, 755:193-201.
15. Zhu M., Souillac P.O., Ionescu-Zanetti C., Carter S.A., Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 2002, 277:50914-50922.
16. Meng X., Fink A.L., Uversky V.N. The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA. J. Mol. Biol. 2008, 381:989-999.
17. O'Nuallain B., Allen A., Kennel S.J., Weiss D.T., Solomon A., Wall J.S. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry 2007, 46:1240-1247.
18. Abe M., Goto T., Kennel S.J., Wolfenbarger D., Macy S.D., Weiss D.T., Solomon A. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies. Am. J. Clin. Pathol. 1993, 100:67-74.
19. Wall J., Schell M., Murphy C., Hrncic R., Stevens F.J., Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 1999, 38:14101-14108.
20. Eftink M.R. Use of multiple spectroscopic methods to monitor equilibrium unfolding of proteins. Methods Enzymol. 1995, 259:487-512.
21. Milardi D., la Rosa C., Fasone S., Grasso D. An alternative approach in the structure-based predictions of the thermodynamics of protein unfolding. Biophys. Chem. 1997, 69:43-51.
22. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
23. Chen Y.H., Yang J.T., Chau K.H. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 1974, 13:3350-3359.
24. Sugiyama S., Miyata T., Inagi R., Kurokawa K. Implication of the glycoxidation and lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis. Int. J. Mol. Med. 1998, 2:561-565.
25. Bouma B., Kroon-Batenburg L.M., Wu Y.P., Brunjes B., Posthuma G., Kranenburg O., de Groot P.G., Voest E.E., Gebbink M.F. Glycation induces formation of amyloid cross-beta structure in albumin. J. Biol. Chem. 2003, 278:41810-41819.
26. Thorpe S.R., Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003, 25:275-281.
27. Tsunenaga M., Goto Y., Kawata Y., Hamaguchi K. Unfolding and refolding of a type kappa immunoglobulin light chain and its variable and constant fragments. Biochemistry 1987, 26:6044-6051.
28. Schmid F.X. Spectral Methods of Characterizing Protein Conformation and Conformational Changes. Protein structure a practical approach 1989, 251-285. IRL Press at Oxford University Press, Oxford. T.E. Creighton (Ed.).
29. Shaklai N., Garlick R.L., Bunn H.F. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J. Biol. Chem. 1984, 259:3812-3817.
30. Mendez D.L., Jensen R.A., McElroy L.A., Pena J.M., Esquerra R.M. The effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch. Biochem. Biophys. 2005, 444:92-99.
31. Davis D.P., Khurana R., Meredith S., Stevens F.J., Argon Y. Mapping the major interaction between binding protein and Ig light chains to sites within the variable domain. J. Immunol. 1999, 163:3842-3850.
32. Ali J., Younus H. Effect of succinylation of antibodies on their conformation and interaction with the antigen. Biochemistry (Mosc) 2006, 71:1336-1340.
33. Lapolla A., Tonani R., Fedele D., Garbeglio M., Senesi A., Seraglia R., Favretto D., Traldi P. Non-enzymatic glycation of IgG: an in vivo study. Horm. Metab. Res. 2002, 34:260-264.
34. Huang Z.Q., Kirk K.A., Connelly K.G., Sanders P.W. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 1993, 92:2975-2983.
35. Batuman V. Proximal tubular injury in myeloma. Contrib. Nephrol. 2007, 153:87-104.
36. Teng J., Russell W.J., Gu X., Cardelli J., Jones M.L., Herrera G.A. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004, 84:440-451.
37. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., Ikeda H., Yamagishi S., Kitamoto T., Saito T., Makita Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 2002, 326:117-120.
38. Miyata T., Hori O., Zhang J., Yan S.D., Ferran L., Iida Y., Schmidt A.M. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway, Implications for the pathogenesis of dialysis-related amyloidosis. J. Clin. Invest. 1996, 98:1088-1094.
39. Matsunaga N., Anan I., Rosenberg P., Nagai R., Lundstrom O., Horiuchi S., Ando Y., Suhr O.B. Advanced glycation end product is implicated in amyloid-related kidney complications. Scand. J. Clin. Lab. Invest. 2005, 65:263-271.
40. Owen W.F., Hou F.F., Stuart R.O., Kay J., Boyce J., Chertow G.M., Schmidt A.M. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998, 53:1365-1373.
41. Sousa M.M., Du Yan S., Fernandes R., Guimaraes A., Stern D., Saraiva M.J. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 2001, 21:7576-7586.